CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS

Abstract. Thirty-nine patients with a progredient clinical form of chronic multiple sclerosis (MS) were subject to multiple immunization with autologous polyclonal T-cell vaccines. Two years after initiating the vaccine therapy, no evidence for disease progression was noted in 16 patients (41% of total). Neurological improvement was observed in five cases (13%) from the vaccine-treated group. Of 22 control MS patients who did not receive the immunotherapy, only 6 persons (27%) exhibited stabilization of their clinical state. Clinical improvement was not detectable among this group of MS patients. A group of twenty-six MS patients was treated with Rebif, without evidence of disease progression in eleven cases (42%), and distinct neurological improvement noted in one patient (4%) from this group. One year after starting the vaccine therapy, a rise in serum IL-10 was detected in vaccine-treated patients, whereas IL-17 and IL-18 serum levels remained within the initial ranges. A correlation between the serum levels of anti-myelin antibodies and appropriate anti-idiotypic antibodies was revealed in these patients. In general, the results obtained suggest polyclonal T-cell vaccination as a potentially effective treatment approach, both at early and more advanced stages of the disorder.

Т-cell vaccination, multiple sclerosis, cytokines, antimyelin antibodies, anti-idiotypic antibodies

1. Иванова И.П.. Селедцов В.И., Банул Н.В., Самарин Д.М., Селедцова Г.В., Савкин И.В., Ширинский В.С., Пронкина Н.В., Козлов В.А. Получение Т-клеточной вакцины и ее применение для лечения рассеянного склероза // Мед. Иммунология. – 2005. – Т. 7, № 1. – С. 27-32.

2. Иванова И.П., Селедцов В.И., Селедцова Г.В., Мамаев С.В., Потемкин А.В., Селедцов Д.В., Козлов В.А. Индукция антиидиотипического иммунного ответа аутологичной Т-клеточной вакциной у больных рассеянным склерозом // Клеточные технологии в биологии и медицине. – 2008. – № 3. – С. 145-149.

3. Stinissen P., Zhang J., Vandevyver C., Hermans G., Raus J. Gammadelta T cell responses to activated T cells in multiple sclerosis patients induced by T cell vaccination // J. Neuroimmunol. – 1998. – N 87. – P. 94-104.

4. Giuliani F., Yong V. Immune-mediated neurodegeneration and neuroprotection in MS // Int. MS J. – 2003. – N 10. – P. 122-130.

5. Giuliani F., Goodyer C., Antel J., Yong V. Vulnerability of human neurons to T cell-mediated cytotoxicity // J. Immunol. – 2003. – N. 171. – P. 368-379.

6. Okun E., Mattson M., Arumugam T. Involvement of Fc receptors in disorders of the central nervous system // Neuromolecular Med. – 2010. – N 12 (2). – Р. 164-178.

7. Correale J., Lund B., McMillan M., Ko D., McCarthy K., Weiner L. T cell vaccination in secondary progressive multiple sclerosis // J. Neuroimmunol. – 2000. – N 107. – P. 130-139.

8. Correale J., Farez M., Gilmore W. Vaccines for Multiple Sclerosis : Progress to Date // CNS Drugs. – 2008. – N 22. – P. 175-198.

9. Orduno N., Quach T., Sanz1 I. B cells and immunological tolerance // J. Invest. Dermatol. – 2009. – Vol. 129 (2). – P. 278-288.

10. Gutcher I., Urich E., Wolter K., Prinz M., Becher B. Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation // Nat. Immunol. – 2006. – N 7. – P. 946-953.

11. Nicoletti F., Di Marco R., Mangano K., Patti F., Reggio E., Nicoletti A., Bendtzen K., Reggio A. Increased serum levels of interleukin-18 in patients with multiple sclerosis // Neurology. – 2001. – N 57 (2). – P. 342-344.

12. Huang W.X., Huang P., Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis // Multiple Sclerosis Jornal. – 2004. – N 10. – P. 482-487.

13. Gutcher I., Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation // J. Clin. Invest. – 2007. – Vol. 117. – P. 1119-1127.